This Biotech with Breakout MS Drug Draws Big Investment
A breakout multiple sclerosis drug can change a biotech's trajectory. This article digs into an $8 million investment...
Consistency year to year matters for goals like retirement or college funding. This primer outlines how to assess return stability across periods.
24,555 articlesA breakout multiple sclerosis drug can change a biotech's trajectory. This article digs into an $8 million investment...
Eli Lilly has been a standout growth stock thanks to GLP-1 drug demand. Could a stock split be on the horizon? This g...
The second half of 2026 could reward investors who pick AI stock winners with durable competitive advantages. This gu...
Looking for dividend stocks with real upside? This guide highlights two dependable names that could help you double y...
Alaska Air Group stock surged this week as investors weighed fuel-cost pressures against resilient demand and discipl...
As Berkshire's new leader, Greg Abel faces a massive cash pile. This article examines why Alphabet is the target, wha...
Selling a home isn’t just about the sale price. The tax implications of selling a house can significantly affect your...
C3.AI has faced a rough run, leaving investors wondering if a comeback is possible. This article breaks down the fact...
loandepot reports $108m loss for 2025, reflecting a tougher fourth quarter even as annual revenue and pull-through ma...
UBS boosts its price target on Xcel Energy to $89 while maintaining a Buy rating, saying the stock could year-end hig...
As investors seek clarity in a shifting media world, Newsmax’s Q1 2026 earnings offer clues about growth, profitabili...
A 73-year-old widow with $2.1M confronts a $96,000 tax bill tied to her late husband's IRA beneficiary decision. Here...